Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

Neuro-Oncology

Volumn 12, Issue 3, 2010, Pages 274-282

  Polley, Mei Yin C ^a   Lamborn, Kathleen R ^a   Chang, Susan M ^a   Butowski, Nicholas ^a   Clarke, Jennifer L ^a   Prados, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumors; Clinical trial endpoints; Glioma; Progression free survival; Temozolomide

Indexed keywords

CIS RETINOIC ACID; ERLOTINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; ETHNICITY; FEMALE; GLIOBLASTOMA; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; BRAIN TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952317096     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop034     Document Type: Article

References (17)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med. 2005;352:987-996.
2. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60:353-357.
3. Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005;61:1454-1459.
4. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579-584.
5. Macdonald DR, Casclno TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
6. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-719.
7. Mantel N, Byar DP. Evaluation of response-time data Involving transient states: an Illustration using heart-transplant data. J Am Stat Assoc. 2006;69:81-86.
8. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26:3913-3915.
9. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.
10. Buyse M, Burzykowski T, Carroll K. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218-5224. (Pubitemid 350232253)
11. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol. 2008;26: 1987-1992.
12. Ballman KV, Buckner JC, Brown PD, et al. The relationship between sixmonth progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncology. 2006;9:29-38.
13. Lamborn KR, Alfred Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent highgrade gliomas. Neuro-Oncology. 2008;10:162-170.
14. Clarke JL, Chang SM. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009. in press.
15. Chamberlain M, Glantz M, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83.
16. Taal W, Brandsma D, de Bruin H, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113: 405-410.
17. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192-2197.